Find a Treatment Center

Investor Relations

Contact Us

KiteKonnect®

Press Releases

Filter By Year

2023

June 01, 2023
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

May 17, 2023
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 16, 2023
Gilead Appoints Cindy Perettie Executive Vice President of Kite

May 16, 2023
Gilead Appoints Cindy Perettie Executive Vice President of Kite

March 21, 2023
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

February 22, 2023
Kite Completes Acquisition of Tmunity
February 09, 2023
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
February 02, 2023
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

January 30, 2023
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Filter By Year